Adherex Initiates U.S. Phase Ib/II Trial with ADH-1

Adherex Technologies has initiated a Phase Ib/II clinical trial of ADH-1 (Exherin(TM)) at the M.D. Anderson Cancer Center in Houston in advanced cancer patients who express the tumor molecular target N-cadherin.

This study will explore a "daily x 5" dosing schedule with daily dosing Monday through Friday every three weeks. The study, the company's second Phase Ib/II trial with ADH-1, is designed to define the maximum-tolerated dose and to evaluate the safety, tolerability and antitumor activity of repeated and ascending doses of ADH-1.

The effect of the drug on tumor vasculature will be assessed in some patients through dynamic contrast enhanced MRI. The trial is expected to enroll approximately 40 patients whose tumors express N-cadherin.